Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Immunogen Inc (NQ: IMGN ) N/A UNCHANGED Last Price Updated: 4:00 PM EST, Feb 9, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Immunogen Inc < Previous 1 2 ... 6 7 8 9 10 11 12 13 Next > ImmunoGen Presents Findings from Expansion Cohorts in Phase 1b/2 Study of Pivekimab Sunirine with Vidaza® and Venclexta® in Acute Myeloid Leukemia at ASH December 10, 2022 From ImmunoGen, Inc. Via Business Wire ImmunoGen Announces Clinical Collaboration with Gilead to Evaluate Pivekimab Sunirine in Combination with Magrolimab in Relapsed/Refractory Acute Myeloid Leukemia December 09, 2022 From ImmunoGen, Inc. Via Business Wire Mirati Plays Catch-Up With Amgen, Gilead's 2nd Try With AIDS Drug, Cytokinetics' Adcom Test And More: Key Nov FDA Decisions For Biotech Investors December 02, 2022 Food and Drug Administration decisions and advisory committee verdicts slated for November were mostly positive. New molecular entity approvals so far this year trail 2021’s tally by about 35%. Via Benzinga Looking Into Immunogen's Return On Capital Employed November 28, 2022 Via Benzinga After FDA Approval For Ovarian Cancer Drug, ImmunoGen Becomes Top Pick For This Analyst November 16, 2022 Via Benzinga ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) December 01, 2022 From ImmunoGen, Inc. Via Business Wire Research and Development of Advanced Therapeutics for Ovarian Cancer Fueling Hope December 01, 2022 EQNX::TICKER_START (OTCQB:BVAXF),(NASDAQ:CTIC),(NASDAQ:SGEN),(NYSE:MRK),(NASDAQ:IMGN) EQNX::TICKER_END Via FinancialNewsMedia Topics Intellectual Property Exposures Intellectual Property Expert Ratings for Immunogen November 16, 2022 Via Benzinga Why Jim Cramer Sees 'Another Bad Quarter Ahead' For Ford, And What Will Turn Things Around November 23, 2022 On CNBC’s "Mad Money Lightning Round," Jim Cramer said Vista Outdoor Inc (NYSE: VSTO) can be "bought here. I would not push it, though." Via Benzinga ImmunoGen Appoints Daniel Char as Senior Vice President and Chief Legal Officer November 21, 2022 From ImmunoGen, Inc. Via Business Wire Vodafone, Getty Images Holdings, Haynes International And Some Other Big Stocks Moving Lower On Tuesday November 15, 2022 U.S. stocks traded higher, with the Nasdaq gaining more than 200 points on Tuesday. Here are some big stocks recording losses in today’s session. Via Benzinga PDS Biotechnology To Rally Around 129%? Here Are 5 Other Price Target Changes For Tuesday November 15, 2022 Via Benzinga Why Fast Radius Shares Plunged Around 48%; Here Are 103 Biggest Movers From Yesterday November 16, 2022 Gainers Satixfy Communications Ltd. (NYSE: SATX) shares gained 140.7% to settle at $31.80 on Tuesday. Via Benzinga HUYA, Tencent Music Entertainment, Taiwan Semiconductor Manufacturing, And Some Other Big Stocks Moving Higher In Today's Pre-Market Session November 15, 2022 U.S. stock futures traded higher this morning. Here are some big stocks recording gains in today’s pre-market trading session. Via Benzinga FDA Grants Conditional Approval To First Antibody Drug Conjugate From ImmunoGen For Pretreated Ovarian Cancer November 15, 2022 Via Benzinga ImmunoGen Announces FDA Accelerated Approval of ELAHERE™ (mirvetuximab soravtansine-gynx) for the Treatment of Platinum-Resistant Ovarian Cancer November 14, 2022 From ImmunoGen Inc. Via Business Wire Recap: Immunogen Q3 Earnings November 04, 2022 Immunogen (NASDAQ:IMGN) reported its Q3 earnings results on Friday, November 4, 2022 at 06:30 AM. Here's what investors need to know about the announcement. Earnings Immunogen missed estimated earnings... Via Benzinga ImmunoGen Reports Recent Progress and Third Quarter 2022 Financial Results November 04, 2022 From ImmunoGen, Inc. Via Business Wire Preview: Immunogen's Earnings November 03, 2022 Immunogen (NASDAQ:IMGN) is set to give its latest quarterly earnings report on Friday, 2022-11-04. Here's what investors need to know before the announcement. Analysts estimate that Immunogen will... Via Benzinga ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) November 01, 2022 From ImmunoGen, Inc. Via Business Wire Earnings Scheduled For November 4, 2022 November 04, 2022 Companies Reporting Before The Bell • Sprott (NYSE:SII) is likely to report quarterly earnings at $0.49 per share on revenue of $49.95 million. • Telefonica (NYSE:TEF) is likely to report earnings for... Via Benzinga Provention Bio's Second Try, Apellis's Eye Disorder Drug Review, 3 Adcom Verdicts And More: November's Key PDUFA Catalysts Biotech Investors Must Know November 01, 2022 October proved to be a mixed month for the Food and Drug Administration’s regulatory decisions. Two new molecular entities, or NMEs, were approved during the month, bringing the tally for the... Via Benzinga ImmunoGen Announces Departure of Chief Commercial Officer November 01, 2022 From ImmunoGen, Inc. Via Business Wire ImmunoGen Presents Retrospective Analysis of Extended Treatment Benefit from Multiple Trials of Mirvetuximab Soravtansine in Ovarian Cancer at ESGO October 28, 2022 From ImmunoGen, Inc. Via Business Wire ImmunoGen Announces Conference Call to Discuss Its Third Quarter 2022 Operating Results October 20, 2022 From ImmunoGen Inc. Via Business Wire ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) October 03, 2022 From ImmunoGen, Inc. Via Business Wire ImmunoGen Presents Comprehensive Updates for Mirvetuximab Soravtansine Combination Data in Ovarian Cancer at IGCS September 29, 2022 From ImmunoGen, Inc. Via Business Wire ImmunoGen Announces Webcast of Presentation and Q&A at Upcoming Guggenheim Nantucket Therapeutics Conference September 14, 2022 From ImmunoGen, Inc. Via Business Wire ImmunoGen Presents Additional Analyses Evaluating Mirvetuximab Soravtansine in Ovarian Cancer at ESMO September 11, 2022 From ImmunoGen, Inc. Via Business Wire Benzinga's Top Ratings Upgrades, Downgrades For September 9, 2022 September 09, 2022 Upgrades Via Benzinga < Previous 1 2 ... 6 7 8 9 10 11 12 13 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.